Insulet Corporation enters its Q1 2026 earnings release — due after the close on May 7 — with a sharp divergence between a battered stock price and the most call-heavy options positioning it has seen all year.
The options signal is the standout this week. The put/call ratio has collapsed to 0.72, nearly 2.5 standard deviations below its 20-day average of 1.03. That is the lowest reading in 52 weeks — a reversal from months of consistent put-heavy positioning that ran above 1.10 through most of March and April. The shift points to a meaningful pickup in call buying ahead of earnings, suggesting the options market has re-priced around the possibility of a positive surprise, even as the stock has slid 8.4% on the week and 18% over the past month.
Short interest tells a less agitated story. At 3.7% of the free float, the short position is real but not extreme. What is notable is the direction of travel: shorts peaked near 4.5% of the float around April 23 — at over 3.16 million shares — and have since pulled back roughly 16% to around 2.64 million shares. That retreat coincides with a cost-to-borrow that remains low at 0.49%, ticking up about 24% on the week but still well inside 1%. Availability in the lending market is wide open, with utilization under 1% against a 52-week peak of 2.69% — plenty of room for incremental short-sellers, but no sign they are rushing in. The ORTEX short score sits at 34.6, benign territory, and has been sliding from above 37 two weeks ago. Overall, the positioning picture is one of shorts quietly exiting rather than pressing into earnings.
The Street is cautious on valuation but structurally still onside with the bull case. The mean analyst price target is $310, implying roughly 85% upside from the $167.53 close — a large gap that partly reflects the stock's sharp de-rating rather than a wave of upgrades. Goldman Sachs trimmed its target to $277 from $326 on April 9 while holding Buy; BTIG lowered to $260 from $320 today but also kept its Buy rating. The more pointed moves came from Citigroup and Rothschild, which both downgraded to Neutral in April, cutting from $338 and $380 respectively. Most of the Street is still constructive — the analyst return potential reads at 94.8% — but the downgrade pair signals growing nervousness about near-term execution. The RSI-14 at 28.5 flags the stock as technically oversold. The PE multiple has compressed by roughly 5.8 points over the past 30 days to 24.1x, and EV/EBITDA has eased to 13.9x. Bulls point to the Q4 2025 print — $784 million in revenue, up 31% year-over-year — and the ongoing Omnipod 5 international rollout as the core reason to stay long. Bears flag a roughly 50% collapse in drug delivery revenues and rising competition in the insulin pump market as the risks that have already hammered the stock nearly 40% year-to-date.
The only prior earnings reaction data available is the February 26 Q4 print, where PODD fell less than 1% the next day before drifting a further 2.9% over the following week. That modest reaction is a slim read-through, but it suggests the market's instinct on the last print was to sell slowly rather than aggressively. Peer SYK is down 8.1% on the week — a similarly rough stretch for the broader med-tech space — while LIVN shed 6% over the same period. SIBN and ATEC bucked the trend with gains of 9-10%, a reminder that the selloff is stock-specific rather than purely sector-driven.
The print after the close on May 7 is therefore squarely about whether Omnipod 5 US momentum is holding — and whether management can credibly defend the full-year revenue guide given ongoing drug-delivery headwinds. The call-heavy options shift heading into that event is the clearest near-term signal worth watching.
See the live data behind this article on ORTEX.
Open PODD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
